Is SLGL a good stock to buy right now?

Based on our 6-factor quantitative model, Sol-Gel Technologies Ltd. (SLGL) receives a "Buy" rating with a composite score of 58.2/100. It is ranked #44 out of 4,446 stocks. Key factor scores: Quality 42/100, Value 29/100, Momentum 98/100. The timing signal is "Bullish". This is quantitative analysis only — not investment advice.

What is the stock rating for SLGL?

Sol-Gel Technologies Ltd. (SLGL) has a "Buy" rating and 4-star score. The composite score of 58.2 ranks it #44 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is SLGL in?

Sol-Gel Technologies Ltd. operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $237 million. It is classified as a micro-cap stock.

Does SLGL pay a dividend?

SLGL does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is SLGL's P/E ratio?

P/E ratio data is not currently available for SLGL, which may indicate the company is not yet profitable.

How profitable is SLGL?

SLGL's quality factor score is 42/100. Gross margin: 100.0%. ROE: -146.7% vs sector average -44.3%. High margins suggest pricing power and competitive moats.

How is SLGL valued compared to peers?

SLGL's value factor score is 29/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is SLGL's debt level?

SLGL's debt-to-equity ratio is 0%. Sector average: 31%. Low leverage suggests conservative financial management.

SLGL has a beta of 1.69, meaning it amplifies market moves. Stability score: 39/100.

Does SLGL have high short interest?

SLGL's short interest factor score is 69/100 (higher = less short selling). Moderate short interest.

SLGL Stock Analysis — Sol-Gel Technologies Ltd. Price Target & Forecast 2027

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
SLGL	-9.52%	-3.50%	+12.07%	+102.44%	+14,026.51%	-	-	-
Industry Proxy XLV	-1.76%	-4.39%	-3.74%	-3.00%	+3.85%	-	-	-
U.S. Market SPY	-1.52%	-2.78%	-2.23%	-2.33%	+19.18%	-	-	-
Alpha vs Market	-8.01%	-0.71%	+14.31%	+104.77%	+14,007.33%	-	-	-
Alpha vs Sector	-7.76%	+0.89%	+15.82%	+105.44%	+14,022.67%	-	-	-

Metric	SLGL	Benchmark
P/E Ratio	-6.2x	-117%
EV/EBITDA	—	—
Price / Book	9.1x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
JNJ JOHNSON & JOHNSON	61	50	69	65	21.9x	32.9%	67.8%	29.0%	6.9%	51.0x	$584.6B	VS
HOLX HOLOGIC INC	59	50	58	55	31.4x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
RPRX Royalty Pharma plc	59	50	70	62	11.3x	18.3%	100.0%	76.9%	13.4%	92.0x	$19.6B	VS
SLGL Sol-Gel Technologies Ltd.	58	42	29	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$237M
INVA Innoviva, Inc.	58	50	76	53	15.4x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
GILD GILEAD SCIENCES, INC.	58	50	68	61	23.9x	33.5%	78.7%	25.8%	11.7%	110.0x	$182.0B	VS
FONR FONAR CORP	57	50	57	61	11.1x	6.5%	88.3%	10.1%	-0.7%	33.0x	$117M	VS
NATR NATURES SUNSHINE PRODUCTS INC	57	50	52	71	21.0x	12.4%	72.1%	4.4%	16.1%	59.0x	$440M	VS
BMY BRISTOL MYERS SQUIBB CO	56	50	70	50	17.0x	38.8%	73.1%	15.2%	0.2%	242.0x	$123.5B	VS
MSA MSA Safety Inc	55	50	67	54	27.5x	18.9%	46.7%	14.4%	1.3%	42.0x	$7.2B	VS
UTHR UNITED THERAPEUTICS Corp	55	50	71	57	18.7x	18.0%	88.4%	40.7%	11.8%	11.0x	$23.2B	VS

Key Ratio	TTM	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Gross Margin %	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	1.0%	0.0%	0.0%
Operating Margin %	-1.0%	-1.0%	-18.9%	-4.2%	0.1%	-3.4%	-1.1%	-259.9%	-181.8%	0.0%	0.0%
EBITDA Margin %	-0.9%	-0.9%	-17.3%	-3.7%	0.1%	-3.2%	-1.0%	-243.7%	-178.7%	0.0%	0.0%
Net Margin %	-0.9%	-0.9%	-17.5%	-3.8%	0.1%	-3.3%	-1.1%	-249.6%	-181.4%	0.0%	0.0%
FCF Margin %	-120.4%	-120.4%	-1,149.5%	-248.6%	-25.1%	-292.9%	-100.8%	-19,007.0%	-14,950.6%	-	-
ROE %	-1.5%	-0.3%	-0.7%	-0.3%	0.1%	-0.6%	-0.4%	-5.7%	0.8%	0.7%	0.0%
ROA %	-1.2%	-0.3%	-0.6%	-0.3%	0.1%	-0.5%	-0.4%	-0.8%	-2.4%	0.0%	0.0%
ROIC %	-1.3%	-1.3%	-1.4%	-0.4%	0.1%	-1.9%	-11.8%	-5.2%	-6.9%	0.0%	0.0%

Line Item	TTM	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$12M	$12M	$2M	$4M	$31M	$9M	$23M	$129K	$174K	$0	$0
	$12M	$12M	$2M	$4M	$31M	$9M	$23M	$129K	$174K	$0	—
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	0.0%	0.0%
	—	$6M	$7M	$7M	$8M	$11M	$8M	$6M	$6M	$4M	$2M
Research & Development	—	$18M	$24M	$13M	$20M	$28M	$41M	$28M	$26M	$17M	$7M
Depreciation	—	$233K	$342K	$562K	$880K	$946K	$887K	$762K	$471K	$359K	$300K
	-$12M	-$12M	-$29M	-$16M	$3M	-$30M	-$26M	-$34M	-$32M	-$21M	—
EBIT	-$12M	-$11M	-$27M	-$15M	$3M	-$29M	-$25M	-$32M	-$32M	-$21M	-$10M
EBITDA	-$10M	-$10M	-$27M	-$14M	$4M	-$28M	-$24M	-$31M	-$31M	-$20M	-$9M
Operating Margin	-104.1%	-104.1%	-1885.8%	-418.3%	9.5%	-344.7%	-113.3%	-25985.3%	-18179.9%	0.0%	0.0%
EBITDA Margin	-89.7%	-89.7%	-1730.8%	-369.8%	13.1%	-323.2%	-103.4%	-24372.9%	-17871.8%	0.0%	0.0%
	—	—	—	—	$0	$0	$33K	$0	$0	—	—
	-$11M	-$11M	-$27M	-$15M	$3M	-$29M	-$25M	-$32M	-$32M	-$21M	-$10M
Net Margin	-91.7%	-91.7%	-1752.8%	-384.3%	10.3%	-333.9%	-107.4%	-24963.6%	-18142.5%	0.0%	0.0%
	$-0.38	$-0.38	$-1.01	$-0.65	$0.14	$-1.30	$-1.26	$1.80	$5.02	$3.30	$1.53
Diluted EPS	$-0.38	$-0.38	$-1.01	$-0.65	$0.14	$-1.30	$-1.26	$1.80	$5.02	$3.30	$1.53
Weighted Avg Basic	—	28M	27M	23M	23M	23M	20M	18M	6M	6M	6M
Weighted Avg Diluted	—	28M	27M	23M	24M	23M	20M	18M	6M	6M	6M

Sol-Gel Technologies Ltd. (SLGL) Stock Analysis — March 2026 Rating, Price, and Forecast

Last updated: March 2026

Company Overview — What Does Sol-Gel Technologies Ltd. Do?

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. Sol-Gel Technologies Ltd. (SLGL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Alon Seri-Levy and employs approximately 50 people. With a market capitalization of $237M, SLGL is one of the notable companies in the Healthcare sector.

Sol-Gel Technologies Ltd. (SLGL) Stock Rating — Buy (March 2026)

As of March 2026, Sol-Gel Technologies Ltd. receives a Buy rating with a composite score of 58.2/100 and 4 out of 5 stars from the Blank Capital Research quantitative model.SLGL ranks #44 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Sol-Gel Technologies Ltd. ranks #1 of 842 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SLGL Stock Price and 52-Week Range

Sol-Gel Technologies Ltd. (SLGL) currently trades at $83.97. The stock lost $1.34 (1.6%) in the most recent trading session. Recent trading volume was 39K shares, suggesting relatively thin trading activity.

Is SLGL Overvalued or Undervalued? — Valuation Analysis

Sol-Gel Technologies Ltd. (SLGL) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 9.10x, versus the sector average of 2.99x. The price-to-sales ratio is 5.69x, compared to 3.37x for the average Healthcare stock.

At current multiples, Sol-Gel Technologies Ltd. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Sol-Gel Technologies Ltd. Profitability — ROE, Margins, and Quality Score

Sol-Gel Technologies Ltd. (SLGL) earns a quality factor score of 42/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -146.7%, compared to the Healthcare sector average of -44.3%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -118.1% versus the sector average of -36.6%.

On a margin basis, Sol-Gel Technologies Ltd. reports gross margins of 100.0%, compared to 71.9% for the sector. The operating margin is -104.1% (sector: -65.4%). Net profit margin stands at -91.7%, versus -54.1% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SLGL Debt, Balance Sheet, and Financial Health

Sol-Gel Technologies Ltd. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 5.92x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $19M.

SLGL has a beta of 1.69, meaning it is more volatile than the broader market — a $10,000 investment in SLGL would be expected to move 69.2% more than the S&P 500 on any given day. The stability factor score for Sol-Gel Technologies Ltd. is 39/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Sol-Gel Technologies Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Sol-Gel Technologies Ltd. reported revenue of $12M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-11M. Gross margin was 100.0%. Operating income came in at $-12M.

In FY 2024, Sol-Gel Technologies Ltd. reported revenue of $12M and earnings per share (EPS) of $-0.38. Net income for the quarter was $-11M. Gross margin was 100.0%. Revenue grew 642.5% year-over-year compared to FY 2023. Operating income came in at $-12M.

In FY 2023, Sol-Gel Technologies Ltd. reported revenue of $2M and earnings per share (EPS) of $-1.01. Net income for the quarter was $-27M. Gross margin was 100.0%. Revenue grew -60.0% year-over-year compared to FY 2022. Operating income came in at $-29M.

In FY 2022, Sol-Gel Technologies Ltd. reported revenue of $4M and earnings per share (EPS) of $-0.65. Net income for the quarter was $-15M. Gross margin was 100.0%. Revenue grew -87.6% year-over-year compared to FY 2021. Operating income came in at $-16M.

Over the past 8 quarters, Sol-Gel Technologies Ltd. has demonstrated a growth trajectory, with revenue expanding from $129,000 to $12M. Investors analyzing SLGL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SLGL Dividend Yield and Income Analysis

Sol-Gel Technologies Ltd. (SLGL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SLGL Momentum and Technical Analysis Profile

Sol-Gel Technologies Ltd. (SLGL) has a momentum factor score of 98/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 58/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 69/100 reflects moderate short selling activity.

SLGL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Sol-Gel Technologies Ltd. (SLGL) ranks #1 out of 842 stocks based on the Blank Capital composite score. This places SLGL in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include JOHNSON & JOHNSON (JNJ) with a score of 60.9/100, FONAR CORP (FONR) with a score of 56.7/100, Innoviva, Inc. (INVA) with a score of 57.7/100, HOLOGIC INC (HOLX) with a score of 59.1/100, and BRISTOL MYERS SQUIBB CO (BMY) with a score of 55.5/100.

Comparing SLGL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SLGL vs S&P 500 (SPY) comparison to assess how Sol-Gel Technologies Ltd. stacks up against the broader market across all factor dimensions.

SLGL Next Earnings Date

No upcoming earnings date has been announced for Sol-Gel Technologies Ltd. (SLGL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SLGL? — Investment Thesis Summary

The bull case for Sol-Gel Technologies Ltd. rests on several quantitative strengths. The value score of 29/100 indicates premium valuation. Price momentum is positive at 98/100, suggesting the trend favors buyers. High volatility (stability score 39/100) increases portfolio risk.

In summary, Sol-Gel Technologies Ltd. (SLGL) earns a Buy rating with a composite score of 58.2/100 as of March 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SLGL stock.

Related Resources for SLGL Investors

Explore more research and tools: SLGL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SLGL head-to-head with peers: SLGL vs JNJ, SLGL vs FONR, SLGL vs INVA.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year

Here's Why We're Not At All Concerned With Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Situation

We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Sol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last year

Here's Why We're Not At All Concerned With Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Situation

We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth

Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease